Cambridge Cognition enters virtual clinical trials space with major acquisition



Neuroscience technology company Cambridge Cognition has entered an agreement to acquire eClinicalHealth Ltd (eCH); a full-service digital technology provider that is working on virtual clinical trials for three of the world’s top ten largest pharmaceutical companies.

By integrating eCH’s patient-centric Clinpal platform, Cambridge Cognition will now be able to offer clients a fully integrated solution covering all trial modules – from recruitment to clinical reporting.

Many consider virtual clinical trials to be the future of drug development because they provide the technology to decentralise testing and therefore an opportunity to improve recruitment, retention, trial diversity, trial delays and costs.

A recent survey found that 89 per cent of pharmaceutical companies are currently deploying some form of virtual technology in their trials.

Matthew Stork, Chief Executive Officer of Cambridge Cognition, said:

“The continued rise in virtual trials, and CNS virtual trials in particular, has led us to carefully consider how best to expand our offering quickly to serve this growing market.

“The acquisition of a company with a proven and widely used technology platform, provides Cambridge Cognition the opportunity to capitalise on this market momentum more rapidly than organic development.

“It both makes us immediately more competitive in the CNS virtual trials space and opens the wider Cambridge Cognition business to their established client base of major pharmaceutical, medical device and contract research organisations.”

Many central nervous system (CNS) disorders, such as Depression and Alzheimer’s disease, are particularly suited to virtual trials as at home daily measurements can offer richer information on the progress of the condition.

The past two years have seen more virtual trials for CNS disorders than any other therapeutic area.

This is a natural area of strength for Cambridge Cognition since they are a perfect fit for the suite of digital cognitive assessments and electronic clinical outcomes assessments (eCOA) developed over the last 30 years.

Cambridge Cognition also markets several additional virtual clinical trial modules, such as a medication reminder, that have proven to be attractive add-ons to the core outcomes assessments.

The eCH acquisition now enables the company to complete its offering with a patient-centric platform that connects patients, sites and pharmaceutical companies to coordinate and manage all the essential steps in a virtual clinical trial.

1 Comment

Trending stories

Exit mobile version